Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
APS · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| APS | BIOLOGICAL | See above |
APS is an investigational monoclonal antibody being developed for the treatment of knee osteoarthritis. It is intended to address the pain and functional limitations associated with this condition. The drug is currently in Phase 1 clinical development, meaning it is still being evaluated for safety and is not yet approved for commercial use.
APS is a monoclonal antibody, which is a type of biologic drug designed to bind to a specific target in the body. However, the specific molecular target of APS has not been disclosed. The drug is being studied for its potential to treat knee osteoarthritis, a degenerative joint disease.
APS is being developed by Zimmer Biomet Holdings, Inc., a company traded on the New York Stock Exchange under the ticker symbol ZBH. Zimmer Biomet is a medical device company that also engages in biologic research and development, including the clinical evaluation of APS for knee osteoarthritis.
APS is in Phase 1 clinical development. It has completed one Phase 1 trial, which was an uncontrolled study with 11 participants. The drug is still in the early stages of clinical testing, and it is not yet approved by regulatory authorities. Further studies would be needed to assess its safety and efficacy.
APS has been studied in one clinical trial, identified as NCT02262364, titled "Safety of NStride Autologous Protein Solution in the Treatment of Knee Osteoarthritis (PROGRESS I)." This Phase 1 trial was completed and enrolled 11 participants with knee osteoarthritis. The trial was not randomized or double-blinded and had no control group.